Revolution Medicines: The Company Behind Pancreatic Cancer’s Biggest Advance in Decades
Revolution Medicines got the FDA approval it wanted, but investors barely reacted. Rasonque was cleared on Aug. 26 for certain patients with metastatic pancreatic cancer, just 35 days after the FDA accepted its application and months ahead of schedule.
The stock moved only 0.4%, suggesting much of the good news was already priced in. In a 500-patient Phase 3 trial, patients on Rasonque lived a median 13.2 months, nearly twice the 6.7 months for those receiving standard chemotherapy.
That is a major difference for a disease where only a small share of patients with advanced cancer survive five years. When the results were presented earlier this year, they drew a standing ovation.
Cracking the RAS code
Rasonque targets RAS proteins, the molecular switches that drive tumor growth in most pancreatic cancers. For four decades, scientists called RAS undruggable because its surface is too flat for a conventional drug to grip.
The breakthrough came when UC San Francisco researcher Kevan Shokat target a protein long considered unreachable. Revolution Medicines later acquired Warp Drive Bio and used its technology to develop daraxonrasib, which entered its first patient trials in 2022.
That early demand could quickly turn into meaningful sales. RBC Capital Markets expects about $28M in US revenue this quarter, rising to $148M in Q4, with more than 2K patients already enrolled in the expanded access program.
Longer-term peak sales could reach $11.5B annually per RBC, if the drug holds up across earlier disease stages and other cancer types.
Pharmaceutical intelligence firm Evaluate puts that ceiling even higher at $20B if the drug proves effective in earlier lines and different tumor types.
Approval was only step one
Here's where the bull case gets complicated. The approval covers second-line patients and those who can't tolerate aggressive chemo, not previously untreated patients.
RBC analyst Leonid Timashev noted that some investors had been holding out for a first-line approval, which would have unlocked the largest patient pool immediately.
The drug's flexible label does allow doctors to prescribe it as a first-line therapy for patients who can't handle heavy regimens, which meaningfully expands the addressable market without a formal first-line indication.
Competition is already building. Eli Lilly has been buying oncology assets to expand its cancer business, while Pfizer is developing its own RAS-targeting drugs.
Rasonque also comes with tough side effects, including an acne-like rash in up to 90% of patients, along with diarrhea, fatigue and nausea, which could make long-term use harder for some patients.
RVMD has already climbed 166% this year, including a nearly 40% jump when the trial data landed in April.
By the time the FDA approval arrived, the market had largely moved on, with shares barely budging on the news. RBC expects the broad label to help sales, but the next real test is whether Rasonque can deliver in first-line treatment and open up a much larger market.